

# International Nonproprietary Names for Pharmaceutical Substances (INN)

---

## RECOMMENDED International Nonproprietary Names: List 60

Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances [*Off. Rec. Wld Health Org.*, 1955, **60**, 3 (Resolution EB15.R7); 1969, **173**, 10 (Resolution EB43.R9); Resolution EB115.R4 (EB115/2005/REC/1)], the following names are selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy.

Lists of Proposed (1–96) and Recommended (1–57) International Nonproprietary Names can be found in *Cumulative List No. 12, 2007* (available in CD-ROM only).

## Dénominations communes internationales des Substances pharmaceutiques (DCI)

### Dénominations communes internationales RECOMMANDÉES: Liste 60

Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques [*Actes off. Org. mond. Santé*, 1955, **60**, 3 (résolution EB15.R7); 1969, **173**, 10 (résolution EB43.R9); Résolution EB115.R4 (EB115/2005/REC/1)] les dénominations ci-dessous sont choisies par l'Organisation mondiale de la Santé en tant que dénominations communes internationales recommandées. L'inclusion d'une dénomination dans les listes de DCI recommandées n'implique aucune recommandation en vue de l'utilisation de la substance correspondante en médecine ou en pharmacie.

On trouvera d'autres listes de Dénominations communes internationales proposées (1–96) et recommandées (1–57) dans la *Liste récapitulative No. 12, 2007* (disponible sur CD-ROM seulement).

## Denominaciones Comunes Internacionales para las Sustancias Farmacéuticas (DCI)

### Denominaciones Comunes Internacionales RECOMENDADAS: Lista 60

De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes Internacionales Recomendadas para las Sustancias Farmacéuticas [*Act. Of. Mund. Salud*, 1955, **60**, 3 (Resolución EB15.R7); 1969, **173**, 10 (Resolución EB43.R9); Resolución EB115.R4 (EB115/2005/REC/1)], se comunica por el presente anuncio que las denominaciones que a continuación se expresan han sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas. La inclusión de una denominación en las listas de las Denominaciones Comunes Recomendadas no supone recomendación alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia.

Las listas de Denominaciones Comunes Internacionales Propuestas (1–96) y Recomendadas (1–57) se encuentran reunidas en *Cumulative List No. 12, 2007* (disponible sólo en CD-ROM).

Latin, English, French, Spanish:

Recommended INN

Chemical name or description; Molecular formula; Graphic formula

DCI Recommandée

Nom chimique ou description; Formule brute; Formule développée

DCI Recomendada

Nombre químico o descripción; Fórmula molecular; Fórmula desarrollada

**adiplonum**


adiplon

7-[[2-(3-fluoropyridin-2-yl)-1*H*-imidazol-1-yl]methyl]-2-methyl-8-propyl[1,2,4]triazolo[1,5-*c*]pyrimidine

adiplon

7-[[2-(3-fluoropyridin-2-yl)-1*H*-imidazol-1-yl]méthyl]-2-méthyl-8-propyl[1,2,4]triazolo[1,5-*c*]pyrimidine

adiplón

7-[[2-(3-fluoropiridin-2-il)-1*H*-imidazol-1-il]metil]-2-metil-8-propil[1,2,4]triazolo[1,5-*c*]pirimidinaC<sub>18</sub>H<sub>18</sub>FN<sub>7</sub>**agatolimodum**

agatolimod

*P*-thiothymidylyl-(3'→5')-2'-deoxy-*P*-thiocytidylyl-(3'→5')-2'-deoxy-*P*-thioguanylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-deoxy-*P*-thiocytidylyl-(3'→5')-2'-deoxy-*P*-thioguanylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-deoxy-*P*-thioguanylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-deoxy-*P*-thiocytidylyl-(3'→5')-2'-deoxy-*P*-thioguanylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-deoxy-*P*-thioguanylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-deoxy-*P*-thiocytidylyl-(3'→5')-2'-deoxy-*P*-thioguanylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-thymidine

agatolimod

*P*-thiothymidylyl-(3'→5')-2'-déoxy-*P*-thiocytidylyl-(3'→5')-2'-déoxy-*P*-thioguanylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-déoxy-*P*-thiocytidylyl-(3'→5')-2'-déoxy-*P*-thioguanylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-déoxy-*P*-thioguanylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-déoxy-*P*-thiocytidylyl-(3'→5')-2'-déoxy-*P*-thioguanylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-déoxy-*P*-thioguanylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-déoxy-*P*-thiocytidylyl-(3'→5')-2'-déoxy-*P*-thioguanylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-thymidine



Heavy chain / Chaîne lourde / Cadena pesada  
 EVQLVESGGG LVQPGGSLRL SCAASGFTFS SYGMSWVRQA PGKGLEWVAT 50  
 ITSGGSYTTY VDSVKGRTI SRDRAKNTLY LQMNSLRAED TAVYVCVRIG 100  
 EDALDYWGQG TLVTVSSAST KGPSVFPPLAP SSKSTSGGTA ALGCLVKDYF 150  
 PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVTVVPS SSLGTQTYIC 200  
 NVNHKPSNTK VDKKVEPKSC DKHTTCAA 228

Light chain / Chaîne légère / Cadena ligera  
 DIQMTQSPSS LSASVGRVIT ITCRASQDIA GSLNWLQKQP GKAIKRLIYA 50  
 TSSLDLSDGVPK RFGSGRSGSD YTLTISSLQP EDFATYYCLO YGSFPPTFGQ 100  
 GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150  
 DNALQSGNSQ ESVTEQDSKD STYLSLSTLT LSKADYKHK VYACEVTHQG 200  
 LSSPVTKSFN RGEK 214

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro  
 C22 - C96; C144 - C200; C220 and light chain C214

Glycosylation sites / Sites de glycosylation / Posiciones de glicosilación  
 Heavy chain residue C226 is the site of PEG attachment.

**aleplasininum**

aleplasinin


2-{1-[(4-*tert*-butylphenyl)methyl]-5-(3-methylphenyl)-1*H*-indol-3-yl]-2-oxoacetic acid

aléplasinine

acide [1-[[4-(1,1-diméthyléthyl)phényl]méthyl]-5-(3-méthylphényl)-1*H*-indol-3-yl]oxoacétique

aleplasinina

ácido 2-{1-[(4-*tert*-butilfenil)metil]-5-(3-metilfenil)-1*H*-indol-3-il}-2-oxoacético

C<sub>28</sub>H<sub>27</sub>NO<sub>3</sub>**almorexantum**

almorexant


(2*R*)-2-[(1*S*)-6,7-dimethoxy-1-{2-[4-(trifluoromethyl)phenyl]ethyl}-3,4-dihydroisoquinolin-2(1*H*)-yl]-*N*-methyl-2-phenylacetamide

almorexant

(2*R*)-1-[(1*S*)-6,7-diméthoxy-1-{2-[4-(trifluorométhyl)phényl]éthyl}-3,4-dihydroisoquinoléin-2(1*H*)-yl]-*N*-méthyl-2-phénylacétamide

almorexant

(2*R*)-2-[(1*S*)-6,7-dimetoxi-1-{2-[4-(trifluorometil)fenil]etil}-3,4-dihidroisoquinolin-2(1*H*)-il]-*N*-metil-2-fenilacetamida

C<sub>29</sub>H<sub>31</sub>F<sub>3</sub>N<sub>2</sub>O<sub>3</sub>

**amolimogenum bepiplasmidum\***  
amolimogene bepiplasmid

plasmid DNA vector expressing a hybrid peptide consisting of a 25 amino acid targeting signal sequence fused to the N-terminus of a 236 amino acid peptide derived from fragments of the E6 and E7 genes from HPV types 16 and 18, driven by a cytomegalovirus promoter

## amolimogène bépliplasmide

vecteur constitué d'ADN plasmidique exprimant un peptide hybride composé d'une séquence signal de 25 résidus fusionnée à l'acide aminé N-terminal d'un peptide de 236 résidus constitué de fragments du produit des gènes E6 et E7 du Papillomavirus humain de type 16 et 18 sous contrôle d'un promoteur de cytomegalovirus

## amolimogén bepiplásmido

vector formado por DNA de plásmido que expresa un péptido híbrido que consiste en una secuencia señal de 25 aminoácidos unida al extremo N-terminal de un péptido de 236 aminoácidos constituido por fragmentos del producto de los genes E6 y E7 del Papillomavirus humano tipos 16 y 18, controlado por un promotor de cytomegalovirus

**amsilarotenum**  
amsilarotene

4-[3,5-bis(trimethylsilyl)benzamido]benzoic acid


## amsilarotène

acide 4-[[3,5-bis(triméthylsilyl)benzoyl]amino]benzoïque

## amsilaroteno

ácido 4-[[3,5-bis(trimetilsilil)benzoil]amino]benzoico

$C_{20}H_{27}NO_3Si_2$

**anacetrapibum**  
anacetrapib



(4*S*,5*R*)-5-[3,5-bis(trifluoromethyl)phenyl]-3-[[4'-fluoro-2'-methoxy-5'-(propan-2-yl)-4-(trifluoromethyl)-[1,1'-biphenyl]-2-yl]methyl]-4-methyl-1,3-oxazolidin-2-one

## anacétrapib

(4*S*,5*R*)-5-[3,5-bis(trifluorométhyl)phényl]-3-[[4'-fluoro-2'-méthoxy-5'-(1-méthyléthyl)-4-(trifluorométhyl)biphényl-2-yl]méthyl]-4-méthylloxazolidin-2-one

## anacetrapib

(4*S*,5*R*)-5-[3,5-bis(trifluorometil)fenil]-3-[[4'-fluoro-2'-metoxi-5'-(propan-2-il)-4-(trifluorometil)bifenil-2-il]metil]-4-metiloxazolidin-2-ona



**anrukinzumabum\***  
anrukinzumab


immunoglobulin G1, anti-[*Homo sapiens* interleukin 13 (IL13)] humanized monoclonal IMA-638; gamma1 heavy chain [humanized VH (*Homo sapiens* FR/*Mus musculus* CDR) [8.7.12] -*Homo sapiens* IGHG1\*03, 97R>K (CH1 120), 117L>A (CH2 1.3), 120G>A (CH2 1) (221-218')-disulfide with kappa light chain [humanized V-KAPPA (*Homo sapiens* FR/*Mus musculus* CDR) [10.3.9] -*Homo sapiens* IGKC\*01]; (227-227":230-230")-bisdisulfide dimer

anrukinzumab

immunoglobuline G1, anti-[*Homo sapiens* interleukine 13 (IL13)] anticorps monoclonal humanisé IMA-638; chaîne lourde gamma1 [VH humanisé (*Homo sapiens* FR/*Mus musculus* CDR) [8.7.12] - *Homo sapiens* IGHG1\*03, 97R>K (CH1 120), 117L>A (CH2 1.3), 120G>A (CH2 1)] (221-218')-disulfure avec la chaîne légère kappa [V-KAPPA humanisé (*Homo sapiens* FR/*Mus musculus* CDR) [10.3.9] -*Homo sapiens* IGKC\*01]; dimère (227-227":230-230")-bisdisulfure

anrukinzumab

inmunoglobulina G1, anti-[*Homo sapiens* interleukina 13 (IL13)] anticuerpo monoclonal humanizado IMA-638; cadena pesada gamma1 [VH humanizada (*Homo sapiens* FR/*Mus musculus* CDR) [8.7.12] - *Homo sapiens* IGHG1\*03, 97R>K (CH1 120), 117L>A (CH2 1.3), 120G>A (CH2 1)] (221-218')-disulfuro con la cadena ligera kappa [V-KAPPA humanizada (*Homo sapiens* FR/*Mus musculus* CDR) [10.3.9] -*Homo sapiens* IGKC\*01]; dímero (227-227":230-230")-bisdisulfuro



Heavy chain  $\gamma$ 1 / Chaîne lourde  $\gamma$ 1 / Cadena pesada  $\gamma$ 1

```
EVQLVESGGG LVQPGGSLRL SCAASGFTFI SYAMSWVRQA PGKGLEWVAS 50
ISSGGNTYYP DSVKGRFTIS RDNAKNSLYL QMNSLRAEDT AVYYCARLDG 100
YYFGFAYWQO GTLVTVSSAS TKGPSVFFLA PSSKSTSGGT AALGCLVKDY 150
FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSSLGTQTYI 200
CNVNHKPSNT KVDKKEPKS CDKHTCPCP PAPEALGAPS VLFPPKPKD 250
TLMISRTPEV TCVVVDVSH EPEVKFNWYV DGVEVHNAKT KPREEQYNST 300
YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPVY 350
TLPPSREEMT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTTPVLD 400
SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH EALHNNHYTQK SLSLSPGK 448
```

Light chain  $\kappa$  / Chaîne légère  $\kappa$  / Cadena ligera  $\kappa$

```
DIQMTQSPSS LSASVGDRTV ITCKASESVD NYGKSLMHWY QQKPGKAPKL 50'
LIYRASNLDS GVPKRFSGSG SGTDFTLTIS SLQPEDFATY YCQQSNEDPW 100'
TFGGGTKEVI KRTVAAPSVE IFPPSDEQLK SGTASVVCLL NNFYPREAKV 150'
QWKVDNALQS GNSQESVTEQ DSKDSTYSL S TLTLSKADY EKHKVYACEV 200'
THQGLSSPVT KSFNRGEC 218'
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro  
22-95 22"-95" 23"-92" 23"-92" 138'-198" 138"-198" 145-201 145"-201"  
218'-221 218"-221" 227-227" 230-230" 262-322 262"-322" 368-426 368"-426"

**baminerceptum\***

baminercept

human tumor necrosis factor receptor superfamily member 3 (lymphotoxin- $\beta$  receptor, TNF C receptor)-(2-195)-peptide (fragment of extracellular domain) fusion protein with human immunoglobulin heavy constant  $\gamma$ 1 chain Fc fragment [227 residues, hinge (195-205) des-(1-4), C5>V, CH2 (206-315), CH3 (316-421) des-K<sup>107</sup>]

baminercept

membre 3 de la superfamille des récepteurs du facteur de nécrose tumorale humain (récepteur de la lymphotoxine- $\beta$  ou récepteur du TNF C)-(2-195)-peptide (fragment du domaine extracellulaire) protéine de fusion avec le fragment Fc de la chaîne lourde constante  $\gamma$ 1 de l'immunoglobuline humaine [227 résidues, dés-(1-4)-[C5>V]charnière (195-205), CH2 (206-315), des-K<sup>107</sup>-CH3 (316-421)]

baminercept

miembro 3 de la superfamilia de receptores del factor de necrosis tumoral humano (receptor de la linfoxina- $\beta$  o receptor del TNF C)-(2-195)-péptido (fragmento del dominio extracelular) proteína de fusión con el fragmento Fc de la cadena pesada constante  $\gamma$ 1 de la inmunoglobulina humana [227 restos, des(14)-[C5>V]bisagra (195-205), CH2 (206-315), desK107-CH3 (316-421)]

C<sub>4074</sub>H<sub>6282</sub>N<sub>1134</sub>O<sub>1274</sub>S<sub>68</sub>

Monomer / Monomère / Monómero					
AVPPYASENQ	TCRDQEKEYY	EPQHRICCSR	CPPGTYSVSAK	CSRIRDVTCA	50
TCAENSYNH	WNYLTICQLC	RPCDPVMGLE	EIAPCTSKRK	TQCRCPGGMF	100
CAAWALECTH	CELLSDCPFG	TEAEKDEYV	KGNHCVCPK	AGHFQNTSSP	150
SARCQPHTRC	ENQGLVEAAP	GTAQSDTCK	NPLEPLPEM	SGTMVDKTHH	200
CPCPAPELL	GGPSVFLFP	KPKDTLMISR	TPEVTCVVVD	VSHEDPEVKF	250
NWYVDGVEVH	NAKTKPREEQ	YNSTYRVVSV	LTVLHQDNLN	GKEYKCKVSN	300
KALPAPIEKT	ISKARGQPRE	FQVYTLPPSR	DELTKNQVSL	TCLVKGFYPS	350
DIAVEWESNG	QPENNYKTP	PVLDSGGSFF	LYSKLTVDKS	RWQQGNVFC	400
SVMHEALHNNH	YTQKSLSLSP	G			421

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro  
 12-27 12'-27' 28-41 28'-41' 31-49 31'-49' 52-67 52'-67' 70-85  
 70'-85' 73-93 73'-93' 95-101 95'-101' 108-117 108'-117' 111-136 111'-136'  
 139-154 139'-154' 201-201' 204-204' 236-296 236'-296' 342-400 342'-400'

Glycosylation sites / Sites de glycosylation / Posiciones de glicosilación  
 Asn-9 Asn-9' Asn-146 Asn-146' Asn-272 Asn-272'

**bentamapimodum**

bentamapimod


2-(1,3-benzothiazol-2-yl)-2-[2-({4-[(morpholin-4-yl)methyl]phenyl})methoxy]pyrimidin-4-yl]acetonitrile

bentamapimod

(benzothiazol-2-yl)[2-({4-[(morpholin-4-yl)méthyl]phényl})méthoxy]pyrimidin-4-yl]acétonitrile

bentamapimod

2-(1,3-benzotiazol-2-il)-2-[2-({4-[(morfolin-4-il)metil]fenil)metoxi}]pirimidin-4-il]acetónitrilo

C<sub>25</sub>H<sub>23</sub>N<sub>5</sub>O<sub>2</sub>S

and enantiomer  
 et énantiomère  
 y enantiómero

**berubicinum**


berubicin

(8*S*,10*S*)-10-[(3-amino-4-*O*-benzyl-2,3,6-trideoxy- $\alpha$ -*L*-lyxo-hexopyranosyl)oxy]-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione

bérubicine

(8*S*,10*S*)-10-[(3-amino-4-*O*-benzyl-2,3,6-tridéoxy- $\alpha$ -*L*-lyxo-hexopyranosyl)oxy]-7,8,9,10-tétrahydro-6,8,11-trihydroxy-8-(hydroxyacétyl)-1-méthoxytétracène-5,12-dione

berubicina

(8*S*,10*S*)-10-[(3-amino-4-*O*-bencil-2,3,6-tridesoxi- $\alpha$ -*L*-lixo-hexopiranosil)oxi]-6,8,11-trihidroxi-8-(hidroxiacetil)-1-metoxi-7,8,9,10-tetrahidrotetraceno-5,12-dionaC<sub>34</sub>H<sub>35</sub>NO<sub>11</sub>**besifloxacinum**


besifloxacin

7-[(3*R*)-3-aminoazepan-1-yl]-8-chloro-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid

bésifloxacine

(+) -acide 7-[(3*R*)-3-aminohexahydro-1*H*-azépin-1-yl]-8-chloro-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoléine-3-carboxylique

besifloxacino

ácido 7-[(3*R*)-3-aminoazepan-1-il]-1-ciclopropil-8-cloro-6-fluoro-4-oxo-1,4-dihidroquinolina-3-carboxílicoC<sub>19</sub>H<sub>21</sub>ClFN<sub>3</sub>O<sub>3</sub>**betrixabanum**

betrixaban

*N*-(5-chloropyridin-2-yl)-2-[4-(*N,N*-dimethylcarbamimidoyl)benzamido]-5-methoxybenzamide



bétrixaban

*N*-(5-chloropyridin-2-yl)-2-({4-[(diméthylamino)iminométhyl]benzoyl}amino)-5-méthoxybenzamide

betrixabán

*N*-(5-cloropiridin-2-il)-2-[4-(*N,N*-dimetilcarbamidoiil)benzamido]-5-metoxibenzamida





**briobaceptum\***  
briobacept


aspartyl[1-valine,20-asparagine,27-proline](human tumor necrosis factor receptor superfamily member 13C (BAFF receptor, BlyS receptor 3 or CD268 antigen)-(1-71)-peptidyl (part of the extracellular domain))valyl(human immunoglobulin G1 Fc fragment, *Homo sapiens* IGHG1-(104-329)-peptide) (79-79':82-82')-bisdisulfide dimer

briobacept

aspartyl[1-valine,20-asparagine,27-proline](membre 13C de la superfamille des récepteurs du facteur de nécrose tumorale humain (récepteur du BAFF, récepteur 3 du BlyS ou antigène CD268)-(1-71)-peptidyl (fragment du domaine extracellulaire))valyl(fragment Fc de l'immunoglobuline G1 humaine, *Homo sapiens* IGHG1-(104-329)-peptide) (79-79':82-82')-bisdisulfure du dimère

briobacept

aspartil[1-valina,20-asparagina,27-prolina](miembro 13C de la superfamilia de receptores del factor de necrosis tumoral humano (receptor del BAFF, receptor 3 del BlyS o antígeno CD268)-(1-71)-peptidil (fragmento del dominio extracelular))valil(fragmento Fc de la inmunoglobulina G1 humana, *Homo sapiens* IGHG1-(104-329)-péptido) (79-79':82-82')-bisdisulfuro del dímero



Monomer / Monomère / Monómero

DVRRGPRSLR	GRDAPAPTPC	NPAECFDPLV	RHCVACGLLR	TPRPKPAGAS	50
SPAPRTALQP	QESVGAGAGE	AAVDKTHTCP	PCPAPELLGG	PSVFLFPKPK	100
KDTLMISRTP	EVTQVVVDVS	HEDPEVKFNW	YVDGVEVHNA	KTKPREEQYN	150
STYRVVSVLT	VLHQDWLNGK	EYKCKVSNKA	LPAPIEKTIS	KAKGQPREPQ	200
VYTLPPSRDE	LTKNQVSLTC	LVKGFYPSDI	AVEWESNGQP	ENNYKTTTPPV	250
LDSDGSEFLY	SKLTVDKSRW	QQGNVFSCSV	MHEALHNNHYT	QKSLSLSPG	249

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

20-33 20'-33' 25-36 25'-36' 79-79' 82-82' 114-174 114'-174' 220-278 220'-278'

**cabazitaxelum**  
cabazitaxel


1-hydroxy-7β,10β-dimethoxy-9-oxo-5β,20-epoxytax-11-ene-2α,4,13α-triyl 4-acetate 2-benzoate 13-[(2*R*,3*S*)-3-[[*tert*-butoxy]carbonyl]amino]-2-hydroxy-3-phenylpropanoate]

cabazitaxel

(-)-12b-acétate 12-benzoate et 9-[(2*R*,3*S*)-3-[[1,1-diméthyléthoxy]carbonyl]amino]-2-hydroxy-3-phénylpropanoate] de (2*aR*,4*S*,4*aS*,6*R*,9*S*,11*S*,12*S*,12*aR*,12*bS*)-11-hydroxy-4,6-diméthoxy-4*a*,8,13,13-tétraméthyl-5-oxo-3,4,4*a*,5,6,9,10,11,12,12*a*-décahydro-7,11-méthano-1*H*-cyclodéca[3,4]benzo[1,2-*b*]oxète-9,12,12*b*(2*aH*)-triyle

cabazitaxel

4-acetato 2-benzoato 13-[(2*R*,3*S*)-3-[[*terc*-butoxi]carbonil]amino]-2-hidroxiopropanoato] de 1-hidroxi-7β,10β-dimetoxi-9-oxo-5β,20-epoxitax-11-eno-2α,4,13α-triil

C<sub>45</sub>H<sub>57</sub>NO<sub>14</sub>**cariprazinum**


cariprazine

3-(*trans*-4-{2-[4-(2,3-dichlorophenyl)piperazin-1-yl]ethyl}cyclohexyl)-1,1-dimethylurea

cariprazine

*N'*-(*trans*-4-{2-[4-(2,3-dichlorophényl)pipérazin-1-yl]éthyl}cyclohexyl)-*N,N*-diméthylurée

cariprazina

*N'*-(*trans*-4-{2-[4-(2,3-diclorofenil)piperazin-1-il]etil}ciclohexil)-*N,N*-dimetilureaC<sub>21</sub>H<sub>32</sub>Cl<sub>2</sub>N<sub>4</sub>O**carmegliptinum**


carmegliptin

(4*S*)-1-[(2*S*,3*S*,11*bS*)-2-amino-9,10-dimethoxy-1,3,4,6,7,11*b*-hexahydro-2*H*-benzo[*a*]quinolizin-3-yl]-4-(fluorométhyl)pyrrolidin-2-one

carmégliptine

(4*S*)-1-[(2*S*,3*S*,11*bS*)-2-amino-9,10-diméthoxy-1,3,4,6,7,11*b*-hexahydro-2*H*-pyrido[2,1-*a*]isoquinoléin-3-yl]-4-(fluorométhyl)=pyrrolidin-2-one

carmegliptina


(4*S*)-1-[(2*S*,3*S*,11*bS*)-2-amino-9,10-dimetoxi-1,3,4,6,7,11*b*-hexahidro-2*H*-benzo[*a*]quinolizin-3-il]-4-(fluorometil)pirrolidin-2-onaC<sub>20</sub>H<sub>28</sub>FN<sub>3</sub>O<sub>3</sub>

**cobiprostonum**  
cobiprostone7-((2*R*,4*aR*,5*R*,7*aR*)-2-[(3*S*)-1,1-difluoro-3-methylpentyl]-2-hydroxy-6-oxooctahydrocyclopenta[*b*]pyran-5-yl)heptanoic acid

## cobiprostone

acide 7-((2*R*,4*aR*,5*R*,7*aR*)-2-[(3*S*)-1,1-difluoro-3-méthylpentyl]-2-hydroxy-6-oxooctahydrocyclopenta[*b*]pyran-5-yl)heptanoïque

## cobiprostona

ácido 7-((2*R*,4*aR*,5*R*,7*aR*)-2-[(3*S*)-1,1-difluoro-3-metilpentil]-2-hidroxi-6-oxooctahidrociclopenta[*b*]piran-5-il)heptanoicoC<sub>21</sub>H<sub>34</sub>F<sub>2</sub>O<sub>5</sub>**conestatum alfa\***  
conestat alfahuman plasma protease C1 inhibitor (C1 esterase inhibitor)  
(*N,O*-glycosylated recombinant protein expressed in the mammary gland of transgenic rabbits), glycoform  $\alpha$ 

## conestat alfa

inhibiteur de la protéase plasmatique C1 humain (inhibiteur de l'estérase C1) (protéine *N,O*-glycosylée recombinante exprimée dans la glande mammaire de lapines transgéniques), glycoforme  $\alpha$ 

## conestat alfa

inhibidor de la proteasa plasmática C1 humana (inhibidor de la esterasa C1) (proteína *N,O*-glicosilada recombinante expresada en glándula mamaria de coneja transgénica), glicoforma  $\alpha$ C<sub>2355</sub>H<sub>3745</sub>N<sub>613</sub>O<sub>728</sub>S<sub>17</sub>

NP NATSSSSQ	DPESLQDRGE	GKVATTIVISK	MLFVEPILEV	SSLPTTNSST	50
NSÄTKITANT	TDEPTQPTT	EPTTQPTIQP	TQPTTQLPTD	SPTQPTTGSF	100
CPGPVTLCSÐ	LESHSTEAVL	GDA LVD FSLK	LYHAFSAMKK	VETNMAFSPF	150
SIASLLTQVL	LGAGENTKTN	LESILSYPKD	FTCVHQALKG	FTTKGVTSVS	200
QIFHSPDLAI	RDTFVNASRT	LYSSSPRVLS	NNSDANLELI	NTWVAKNTNN	250
KISRLLDSL P	SDTRLVLLNA	IYLSAKWKT	FDPKTRMEP	FHKNSVIKV	300
PMMNSKYPV	AHFIDQTLKA	KVGLQLSHN	LSLVILVPQN	LKHRLEDMEQ	350
ALSPSVFKAI	MEKLEMSKFO	PTLLTLPRIK	VTTSDMLSI	MEKLEFFDFS	400
YDLNLCGLTE	DPDLQVSAMQ	HQTVLELTET	GVEAAAASAI	SVARTLLVFE	450
VQQPFLLFVLW	DQQHKFPVFM	GRVYDPRA			478

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro  
101-406 108-183Glycosylation sites / Sites de glycosylation / Posiciones de glicosilación  
Asn-3 Thr-26 Ser-42 Asn-47 Thr-49 Asn-59 Thr-61  
Thr-66 Thr-70 Thr-74 Asn-216 Asn-231 Asn-250 Asn-330

**dacetuzumabum\***

dacetuzumab

immunoglobulin G1, anti-[*Homo sapiens* CD40 (TNF receptor superfamily member 5, TNFRSF5)] humanized monoclonal SGN-40 (or huS2C6); gamma1 heavy chain [humanized VH (*Homo sapiens* FR/*Mus musculus* CDR) [8.8.7] -*Homo sapiens*IGHG1\*03, 97R>K (CH1 120)] (217-219')-disulfide with kappa light chain humanized V-KAPPA (*Homo sapiens* FR/*Mus musculus* CDR) [11.3.9] -*Homo sapiens* IGKC\*01]; (223-223":226-226")-bisdisulfide dimer

dacétuzumab

immunoglobuline G1, anti-[*Homo sapiens* CD40 (membre 5 de la superfamille des récepteurs du TNF, TNFRSF5)] anticorps monoclonal humanisé SGN-40 (ou huS2C6); chaîne lourde gamma1 [VH humanisé (*Homo sapiens* FR/*Mus musculus* CDR) [8.8.7] -*Homo sapiens* IGHG1\*03, 97R>K (CH1 120)] (217-219')-disulfure avec la chaîne légère kappa [V-KAPPA humanisé (*Homo sapiens* FR/*Mus musculus* CDR) [11.3.9] -*Homo sapiens* IGKC\*01]; dimère (223-223":226-226")-bisdisulfure

dacetuzumab

inmunoglobulina G1, anti-[*Homo sapiens* CD40 (miembro 5 de la superfamilia de receptores del TNF, TNFRSF5)] anticuerpo monoclonal humanizado SGN-40 (o huS2C6); cadena pesada gamma1 [VH humanizado (*Homo sapiens* FR/*Mus musculus* CDR) [8.8.7] -*Homo sapiens* IGHG1\*03, 97R>K (CH1 120)] (217-219')-disulfuro con la cadena ligera kappa [V-KAPPA humanizada (*Homo sapiens* FR/*Mus musculus* CDR) [11.3.9] -*Homo sapiens* IGKC\*01]; dímero (223-223":226-226")-bisdisulfuro

C<sub>6452</sub>H<sub>9964</sub>N<sub>1732</sub>O<sub>1998</sub>S<sub>42</sub>

Heavy chain / Chaîne lourde / Cadena pesada

EVQLVESGGG	LVQPGGSLRL	SCAASGYST	GYIHWVROA	PGKLEWVAR	50
VIPNAGTSTY	NQKFKGRFTL	SVDNSKNTAY	LQMNSLRAED	TAVYYCAREG	100
IYWWGQGTLLV	TVSSASTKGP	SVFPLAPSSK	STSGGTAALG	CLVKDYFPEP	150
VTVSWNSGAL	TSGVHTFFAV	LQSSGLYSLS	SVVTVPSSSL	GTQTYICNVN	200
HKPSNTKVDK	KVEPKSCDKT	HTCPPCPAPE	LLGGPSVFLF	PKPKDTLMI	250
SRTPEVTCVV	VDVSHEDPEV	KFNWYVDGVE	VHNAKTKPRE	EQNSTYRVV	300
SVLTIVLHQDW	LNKGEYKCKV	SNKALPAPIE	KTISKAKGQP	REPVYTLPP	350
SREEMTKNQV	SLTCLVKGFY	PSDIAVEWES	NGQPENNYKT	TPPVLDSDGS	400
FFLYSKLTVD	KSRWQQGNVF	SCSVMHLEALH	NHYTQKSLSL	SPGK	444

Light chain / Chaîne légère / Cadena ligera

DIQMTQSPSS	LSASVGDRTV	ITCRSSQSLV	HSNGNTFLHW	YQKPKGKAPK	50'
LLIYTVSNRF	SGVPSRFSGS	GGTDFTLTI	SSLQPEDFAT	YFCSQTHVVP	100'
WTFGGQTKVE	IKRTVAAPSV	FIFPPSDEQL	KSGTASVCL	LNNFYFREAK	150'
VQWVKVDNALQ	SGNSQESVTE	QDSKDYSTYS	SSTLTLSKAD	YEKHKVYACE	200'
VTHQGLSSPV	TKSFNRGEC				219'

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

22-96 22"-96" 23'-93' 23"-93" 139'-199' 139"-199" 141-197 141"-197"  
217-219' 217"-219" 223-223" 226-226" 258-318 258"-318" 364-422 364"-422"

**daporinadum**

daporinad


(2*E*)-*N*-[4-(1-benzoylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)prop-2-enamide

daporinad

(2*E*)-*N*-[4-(1-benzoylpipéridin-4-yl)butyl]-3-(pyridin-3-yl)prop-2-énamide

daporinad

(2*E*)-*N*-[4-(1-benzoilpiperidin-4-il)butil]-3-(piridin-3-il)prop-2-enamida

C<sub>24</sub>H<sub>29</sub>N<sub>3</sub>O<sub>2</sub>

**darinaparsinum**


darinaparsin

L- $\gamma$ -glutamyl-S-(dimethylarsanyl)-L-cysteinylglycine

darinaparsine

L- $\gamma$ -glutamyl-S-(diméthylarsanyl)-L-cystéinylglycine

darinaparsina

L- $\gamma$ -glutamyl-S-(dimetilarsanil)-L-cisteinilglicinaC<sub>12</sub>H<sub>22</sub>AsN<sub>3</sub>O<sub>6</sub>S**dexneбиволolum**


dexneбиволol

(1*R*)-2-((2*R*)-2-[(2*S*)-6-fluoro-3,4-dihydro-2*H*-chromen-2-yl]-2-hydroxyethyl)amino)-1-[(2*R*)-6-fluoro-3,4-dihydro-2*H*-chromen-2-yl]ethanol

dexnéбиволol

(1*R*,1'*R*)-1,1'-[(2*R*,2'*S*)-bis(6-fluoro-3,4-dihydro-2*H*-1-benzopyran-2-yl)]-2,2'-azanediyl-diéthanol

dexneбиволol

(1*R*)-2-((2*R*)-2-[(2*S*)-6-fluoro-3,4-dihydro-2*H*-chromen-2-yl]-2-hydroxyethyl)amino)-1-[(2*R*)-6-fluoro-3,4-dihydro-2*H*-chromen-2-yl]ethanolC<sub>22</sub>H<sub>25</sub>F<sub>2</sub>NO<sub>4</sub>**emricasanum**


emricasan

(3*S*)-3-((2*S*)-2-[*N*-(2-*tert*-butylphenyl)oxamoylamino]propanamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid

emricasan

acide (3*S*)-3-((2*S*)-2-[[[2-(1,1-diméthyléthyl)phényl]amino]=oxoacétyl]amino]propanoyl]amino)-4-oxo-5-(2,3,5,6-tétrafluorophénoxy)pentanoïque

emricasán

ácido (3*S*)-3-((2*S*)-2-[*N*-(2-*tert*-butilfenil)oxamoilamino]=propanamido)-4-oxo-5-(2,3,5,6-tetrafluorofenoxi)pentanoicoC<sub>26</sub>H<sub>27</sub>F<sub>4</sub>N<sub>3</sub>O<sub>7</sub>

**eribaxaban**  
eribaxaban

(2*R*,4*R*)- *N*<sup>1</sup>-(4-chlorophenyl)- *N*<sup>2</sup>-[2-fluoro-4-(2-oxopyridin-1(2*H*)-yl)phenyl]-4-methoxypyrrolidine-1,2-dicarboxamide


éribaxaban

(2*R*,4*R*)-*N*<sup>1</sup>-(4-clorophényl)-*N*<sup>2</sup>-[2-fluoro-4-(2-oxopyridin-1(2*H*)-yl)phényl]-4-méthoxypyrrolidine-1,2-dicarboxamide

eribaxabán

(2*R*,4*R*)- *N*<sup>1</sup>-(4-clorofenil)- *N*<sup>2</sup>-[2-fluoro-4-(2-oxopiridin-1(2*H*)-il)fenil]-4-metoxipirrolidina-1,2-dicarboxamida

C<sub>24</sub>H<sub>22</sub>ClFN<sub>4</sub>O<sub>4</sub>



**ezatiostatam**  
ezatiostat

ethyl [(4*S*)-4-amino-5-ethoxy-5-oxopentanoyl]-*S*-benzyl-L-cysteinyl-D-2-phenylglycinate


ézatiostat

(2*R*)-[(4*S*)-4-amino-5-éthoxy-5-oxopentanoyl]-*S*-benzyl-L-cystéinyl-D-2-phénylglycinate d'éthyle

ezatiostat

(2*R*)-[(4*S*)-4-amino-5-etoxi-5-oxopentanoil]-*S*-bencil-L-cisteinil-D-2-fenilglicinato de etilo

C<sub>27</sub>H<sub>35</sub>N<sub>3</sub>O<sub>6</sub>S



**fasobegronum**  
fasobegron

4'-(2-[[2*R*]-2-(3-chlorophenyl)-2-hydroxyethyl]amino)ethyl)-3-methoxy-[1,1'-biphenyl]-4-carboxylic acid


fasobégron

acide 4'-(2-[[2*R*]-2-(3-clorophényl)-2-hydroxyéthyl]amino)éthyl)-3-méthoxybiphényle-4-carboxylique

fasobegrón

ácido 4'-(2-[[2*R*]-2-(3-clorofenil)-2-hidroxiétel]amino)etil)-[1,1'-bifenil]-3-metoxi-4-carboxílico

C<sub>24</sub>H<sub>24</sub>ClNO<sub>4</sub>



**favipiravirum**

favipiravir


6-fluoro-3-hydroxypyrazine-2-carboxamide

favipiravir

6-fluoro-3-hydroxypyrazine-2-carboxamide

favipiravir

6-fluoro-3-hidroxipirazina-2-carboxamida

C<sub>5</sub>H<sub>4</sub>FN<sub>3</sub>O<sub>2</sub>**fermagatum**

fermagate


diiron(III) tetramagnesium carbonate dodecahydroxide—water (1/4)

fermagate

tétrahydrate de carbonate et bis[(OC-6-11)-hexahydroxyferrate(3<sup>-</sup>)] de tétramagnésium

fermagato

dodecahidróxidocarbonato de dihierro(III) y tetramagnesio—agua(1/4)

CH<sub>12</sub>Fe<sub>2</sub>Mg<sub>4</sub>O<sub>15</sub> · 4 H<sub>2</sub>O**flopristinum**


flopristin

(3*R*,4*R*,5*E*,10*E*,12*E*,14*S*,16*R*,26*aR*)-16-fluoro-14-hydroxy-4,12-dimethyl-3-(propan-2-yl)-3,4,8,9,14,15,16,17,24,25,26,26a-dodecahydro-1*H*,7*H*,22*H*-21,18-azepopyrrolo=[2,1-*c*][1,8,4,19]dioxadiazacyclotetracosine-1,7,22-trione

flopristine

(3*R*,4*R*,5*E*,10*E*,12*E*,14*S*,16*R*,26*aR*)-16-fluoro-14-hydroxy-4,12-diméthyl-3-(1-méthyléthyl)-8,9,14,15,16,17,24,25,26,26a-décahydro-3*H*-21,18-nitrilo-1*H*,22*H*-pyrrolo=[2,1-*c*][1,8,4,19]dioxadiazacyclotétracosine-1,7,22(4*H*)-trione

flopristina

(3*R*,4*R*,5*E*,10*E*,12*E*,14*S*,16*R*,26*aR*)-16-fluoro-14-hidroxi-4,12-dimetil-3-(propan-2-il)-3,4,8,9,14,15,16,17,24,25,26,26a-dodecahidro-1*H*,7*H*,22*H*-21,18-azenopirrolo=[2,1-*c*][1,8,4,19]dioxadiazacyclotetracosina-1,7,22-trionaC<sub>28</sub>H<sub>38</sub>FN<sub>3</sub>O<sub>6</sub>

**folitixorinum**


folitixorin

*N*-{4-[(6*aRS*)-3-amino-1-oxo-1,4,5,6,6*a*,7-hexahydroimidazo=[1,5-*f*]pteridin-8(9*H*)-yl]benzoyl}-L-glutamic acid

folitixorine

acide *N*-{4-[(6*aRS*)-3-amino-1-oxo-1,4,5,6,6*a*,7-hexahydroimidazo[1,5-*f*]ptéridin-8(9*H*)-yl]benzoyl}-L-glutamique

folitixorina

ácido *N*-{4-[(6*aRS*)-3-amino-1-oxo-1,4,5,6,6*a*,7-hexahydroimidazo[1,5-*f*]pteridin-8(9*H*)-il]benzoil}-L-glutámicoC<sub>20</sub>H<sub>23</sub>N<sub>7</sub>O<sub>6</sub>**ibodutantum**


ibodutant

6-methyl-*N*-{1-[[{(1*R*)-1-[[{(1-[(tetrahydro-2*H*-pyran-4-yl)methyl]piperidin-4-yl)methyl]amino]-3-phenyl-1-oxopropan-2-yl)amino]carbonyl]cyclopentyl]-1-benzothiophene-2-carboxamide

ibodutant

*N*-[1-[[{(1*R*)-1-benzyl-2-oxo-2-[[{(1-[(tétrahydro-2*H*-pyran-4-yl)méthyl]pipéridin-4-yl)méthyl]amino]éthyl]carbamoyl]cyclopentyl]-6-méthyl-1-benzothiophène-2-carboxamide

ibodutant

*N*-[1-[[{(1*R*)-1-bencil-2-oxo-2-[[{(1-[(tetrahidro-2*H*-piran-4-il)metil]piperidin-4-il)metil]amino]etil]carbamoil]ciclopentil]-6-metil-1-benzotiofeno-2-carboxamidaC<sub>37</sub>H<sub>48</sub>N<sub>4</sub>O<sub>4</sub>S**imeglimum**


imeglimin

(4*R*)-6-(dimethylamino)-4-methyl-4,5-dihydro-1,3,5-triazin-2-amine

iméglimine

(+)-(6*R*)-1,6-dihydro-*N,N*,6-triméthyl-1,3,5-triazine-2,4-diamine

imeglimina

(4*R*)-6-(dimetilamino)-4-metil-4,5-dihidro-1,3,5-triazin-2-aminaC<sub>6</sub>H<sub>13</sub>N<sub>5</sub>



**Iaromustinum**


Iaromustine

2-(2-chloroethyl)-1,2-bis(methanesulfonyl)-  
*N*-methylhydrazinecarboxamide

Iaromustine

2'-(2-chloroéthyl)-*N*-méthyl-1',2'-bis(méthylsulfonyl)=  
carbamohydraside

Iaromustina

2-(2-cloroetil)-1,2-bis(metanosulfonyl)-*N*-metilhidrazinacarboxamidaC<sub>6</sub>H<sub>14</sub>ClN<sub>3</sub>O<sub>5</sub>S<sub>2</sub>**Ievonebivololum**


Ievonebivolol

(1*S*)-2-({(2*S*)-2-[(2*R*)-6-fluoro-3,4-dihydro-2*H*-chromen-2-yl]-  
2-hydroxyethyl}amino)-1-[(2*S*)-6-fluoro-3,4-dihydro-2*H*-chromen-  
2-yl]ethanol

Iévonébivolol

(1*S*,1'*S*)-1,1'-[(2*R*,2'*S*)-bis(6-fluoro-3,4-dihydro-2*H*-1-benzopyran-  
2-yl)]-2,2'-azanediyl-diéthanol

Ievonebivolol

(1*S*)-2-({(2*S*)-2-[(2*R*)-6-fluoro-3,4-dihydro-2*H*-chromen-2-yl]-  
2-hydroxyetil}amino)-1-[(2*S*)-6-fluoro-3,4-dihydro-2*H*-chromen-  
2-yl]etanolC<sub>22</sub>H<sub>25</sub>F<sub>2</sub>NO<sub>4</sub>**Iinopristinum**

Iinopristin


*N*-{(6*R*,9*S*,10*R*,13*S*,15*aS*,22*S*,24*aS*)-22-[[4-(  
dimethylamino)phenyl]methyl]-6-ethyl-10,23-dimethyl-  
18-[(morpholin-4-yl)methyl]-5,8,12,15,21,24-hexaoxo-13-phenyl-  
1,2,3,5,6,7,8,9,10,11,12,13,14,15,15*a*,16,19,21,22,23,24,24*a*-  
docosahydropyrido[2,1-*f*]pyrrolo[2,1-*h*][1,4,7,10,13,16]=  
oxapentaazacyclonadecin-9-yl]-3-hydroxypyridine-2-carboxamide

Iinopristine

(6*R*,9*S*,10*R*,13*S*,15*aS*,22*S*,24*aS*)-22-[[4-(diméthylamino)=  
phényl]méthyl]-6-éthyl-9-[[[(3-hydroxypyridin-2-yl)carbonyl]amino]-  
10,23-diméthyl-18-[(morpholin-4-yl)méthyl]-13-phényl-  
1,2,3,6,7,9,10,13,14,16,19,22,23,24*a*-tétradécahydro-  
12*H*-pyrido[2,1-*f*]pyrrolo[2,1-*h*][1,4,7,10,13,16]=  
oxapentaazacyclonadécine-5,8,12,15,21,24(15*aH*)-hexone

Iinopristina

*N*-{(6*R*,9*S*,10*R*,13*S*,15*aS*,22*S*,24*aS*)-22-[[4-(dimetilamino)fenil]=  
metil]-6-etil-13-fenil-10,23-dimetil-18-[(morfolin-4-il)metil]-  
5,8,12,15,21,24-hexaoxo-  
1,2,3,5,6,7,8,9,10,11,12,13,14,15,15*a*,16,19,21,22,23,24,24*a*-  
docosahidropirido[2,1-*f*]pirrolo[2,1-*h*][1,4,7,10,13,16]=  
oxapentaazaciclonaadecin-9-il]-3-hidroxiipiridina-2-carboxamida

C<sub>50</sub>H<sub>63</sub>N<sub>9</sub>O<sub>10</sub>

**lucatumumabum\***  
lucatumumab

immunoglobulin G1, anti-[*Homo sapiens* CD40 (TNF receptor superfamily member 5, TNFRSF5)] human monoclonal antibody CHIR-12.12; gamma1 heavy chain [*Homo sapiens* VH [8.8.13] -IGHG1\*03 (CH1 S10>A), no C-terminal lysine] from clone CHIR-12.12 (223-219')-disulfide with kappa light chain [*Homo sapiens* V-KAPPA (IGKV2-28-IGJK3\*01, K12>R) [11.3.9] -IGKC\*01] from clone CHIR-12.12; (229-229':232-232'')-bisdisulfide dimer

lucatumumab

immunoglobuline G1, anti-[*Homo sapiens* CD40 (membre 5 de la superfamille des récepteurs du TNF, TNFRSF5)] anticorps monoclonal humain CHIR-12.12; chaîne lourde gamma1 [*Homo sapiens* VH [8.8.13] -IGHG1\*03 (CH1 S10>A), pas de lysine C-terminale] du clone CHIR-12.12 (223-219')-disulfure avec la chaîne légère kappa [*Homo sapiens* V-KAPPA (IGKV2-28-IGJK3\*01, K12>R) [11.3.9] -IGKC\*01] du clone CHIR-12.12; dimère (229-229':232-232'')-bisdisulfure

lucatumumab

inmunoglobulina G1, anti-[*Homo sapiens* CD40 (miembro 5 de la superfamilia de receptores del TNF, TNFRSF5)] anticuerpo monoclonal humano CHIR-12.12; cadena pesada gamma1 [*Homo sapiens* VH [8.8.13] -IGHG1\*03 (CH1 S10>A), sin lisina C-terminal] del clon CHIR-12.12 (223-219')-disulfuro con la cadena ligera kappa [*Homo sapiens* V-KAPPA (IGKV2-28-IGJK3\*01, K12>R) [11.3.9] -IGKC\*01] del clon CHIR-12.12; dímero (229-229':232-232'')-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

QVQLVESGGG	VVQPRSLRL	SCAASGFTFS	SYGMHWVRQA	PGKGLEWVAV	50
ISYEESNRYH	ADSVKGRFTI	SRDNSKITLY	LQMNSLRTE	TAVYCARDG	100
GIAAPGPDYW	GQGLTVTVSS	ASTKGPVFP	LAPASKSTSG	GTAALGCLVK	150
DYFPEPVTYS	WNSGALTSGV	HTFPVQLQSS	GLYSLSSVVT	VPSSSLGTQT	200
YICNVNHKPS	NTKVDRKVEP	KSCDKTHTCP	PCPAPELLGG	PSVFLPFPKP	250
KDTLMSRTP	EVTQVVDVS	HEDPEVKFNW	YVDGVEVHNA	KTKPREQYN	300
STYRVVSVLT	VLHQDWLNGK	EYKCKVSNKA	LPAPIEKTIS	KAKQPREPQ	350
VYTLPPSREE	MTKNQVSLTC	LVKGFYPSDI	AVEWESNGQP	ENNYKTPFPV	400
LDSDGSFFLY	SKLTVDKSRW	QQGNVFCSCV	MHEALHNYT	QKSLSLSPGK	450

Light chain / Chaîne légère / Cadena ligera

DIVMTQSPFLS	LTVTPEEPAS	ISCRSSQSLL	YNGYNYLDW	YLQKPGQSPQ	50
VLIISLGSNRA	SGVPDRFSGS	GSGTDFTLKI	SRVEAEDVGV	YYCMQARQTP	100
FTFGPGTKVD	IRRTVAAPSV	FIFPPSDEQL	KSGTASVVCL	LNNFYPREAK	150
VQWKVDNALQ	SGNSQESVTE	QDSKDSITYSL	SSTLTLSKAD	YEKHKVYACE	200
VTHQGLSSPV	TKSFNRGEC				219

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Light Chain Intrachain: C23-C93, C149-C199

Heavy Chain Intrachain: C22-C96, C147-C203, C264-C324, C369-C428

Interchain: Light Chain: C219-Heavy Chain 223, Heavy Chain 1 C229-Heavy Chain 2 C229,

Heavy Chain 1 C232 - Heavy Chain 2 C232

**milatuzumabum\***  
milatuzumab

immunoglobulin G1, anti-[*Homo sapiens* CD74 (major histocompatibility complex class II invariant chain)] humanized monoclonal IMMU-115 (or hLL1); gamma1 heavy chain [humanized VH (*Homo sapiens* FR/*Mus musculus* CDR) [8.8.13] -*Homo sapiens* IGHG1\*03] (223-219')-disulfide with kappa light chain [humanized V-KAPPA (*Homo sapiens* FR/*Mus musculus* CDR) [11.3.9] -*Homo sapiens* IGKC\*01]; (229-229':232-232'')-bisdisulfide dimer

## milatuzumab

immunoglobuline G1, anti-[*Homo sapiens* CD74 (chaîne invariante du complexe majeur d'histocompatibilité de classe II)] anticorps monoclonal humanisé IMMU-115 (ou hLL1); chaîne lourde gamma1 [VH humanisé (*Homo sapiens* FR/*Mus musculus* CDR) [8.8.13] - *Homo sapiens* IGHG1\*03] (223-219')-disulfure avec la chaîne légère kappa [V-KAPPA humanisé (*Homo sapiens* FR/*Mus musculus* CDR) [11.3.9] -*Homo sapiens* IGKC\*01]; dimère (229-229':232-232'')-bisdisulfure

## milatuzumab

inmunoglobulina G1, anti-[*Homo sapiens* CD74 (cadena invariable del complejo mayor de histocompatibilidad de clase II)] anticuerpo monoclonal humanizado IMMU-115 (o hLL1); cadena pesada gamma1 [VH humanizado (*Homo sapiens* FR/*Mus musculus* CDR) [8.8.13] - *Homo sapiens* IGHG1\*03] (223-219')-disulfuro con la cadena ligera kappa [V-KAPPA humanizada (*Homo sapiens* FR/*Mus musculus* CDR) [11.3.9] -*Homo sapiens* IGKC\*01]; dímero (229-229':232-232'')-bisdisulfuro

C<sub>6518</sub>H<sub>10066</sub>N<sub>1758</sub>O<sub>2020</sub>S<sub>40</sub>

## Heavy chain / Chaîne lourde / Cadena pesada

QVQLQSQSGSE	LKKPGASVKV	SCRASGYTFT	NYGVNWIQQA	PGQGLQWQMGW	50
INPNTGEPETF	DDDKPKGRFAF	SLDTSVSTAY	LQISSLKADD	TAVYFCSRSR	100
GKNEAWFAYW	GQQLTVTVSS	ASTKGPSVFP	LAPSSKSTSG	GTAALGCLVK	150
DYFPEPVTVS	WNSGALTSGV	HTFPAVLQSS	GLYSLSVSVT	VPSSSLGTQT	200
YICNVNHKFS	NTKVDKRVEP	KSCDKTHTCP	PCPAPELLGG	PSVFLFPPKP	250
KDTLMSRTP	EVTGVVVDVS	HEDPEVKFNW	YVDGVEVHNA	KTKEPEEQYN	300
STYRVVSVLT	VLHQDWLNGK	EYKCKVSNKA	LPAPTEKTIIS	KAKGQPREPQ	350
VYTLPPSREE	MTKNQVSLTC	LVKGFYPSDI	AVEWESNGQP	ENNYKTTTPPV	400
LDSDGSFFLY	SKLTVDKSRW	QQGNVFSCSV	MHEALHNHYT	QKSLSLSPGK	450

## Light chain / Chaîne légère / Cadena ligera

DIQLTQSPPLS	LPVTLGQPAS	ISCRSSQSLV	HRNGNTYLHW	FQQRPGQSPR	50'
LLIYTVSNRF	SGVPRDFSGS	GSGTDFTLKI	SRVEAEDVGV	YFCSQSSHVP	100'
PTFGAGTRLE	IKRTVAAPSV	FIFPPSDEQL	KSGTASVVCL	LNNFYPREAK	150'
VQWVKVDNALQ	SGNSQESVTE	QDSKDSSTYSL	SSTLTLSKAD	YEKHKVYACE	200'
VTHQGLSSPV	TKSFNRGEC				219'

## Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

22-96 22"-96" 23'-93' 23'''-93''' 139'-199' 139'''-199''' 147-203 147"-203"  
219'-223 219'''-223''' 229-229" 232-232" 264-324 264"-324" 370-428 370"-428"

**mirabegronum**  
mirabegron


2-(2-amino-1,3-thiazol-4-yl)-N-[4-(2-((2R)-2-hydroxy-2-phenylethyl)=amino)ethyl]phenyl]acetamide

## mirabégron

2-(2-aminothiazol-4-yl)-N-[4-(2-((2R)-2-hydroxy-2-phényléthyl)=amino)éthyl]phényl]acétamide

## mirabegrón

2-(2-amino-1,3-tiazol-4-il)-N-[4-(2-((2R)-2-fenil-2-hidroxietil)amino)=etil]fenil]acetamida

C<sub>21</sub>H<sub>24</sub>N<sub>4</sub>O<sub>2</sub>S

**monepantelum**


monepantel

*N*-(2-cyano-1-[(2*S*)-5-cyano-2-(trifluoromethyl)phenoxy]propan-2-yl)-4-(trifluoromethylsulfanyl)benzamide

moné pantel

*N*-{(1*S*)-1-cyano-2-[5-cyano-2-(trifluorométhyl)-1-méthylphénoxy]-4-(trifluorométhyl)sulfanyl}benzamide

monepantel

*N*-(2-ciano-1-[(2*S*)-5-ciano-2-(trifluorometil)fenoxi]propan-2-il)-4-(trifluorometilsulfanil)benzamidaC<sub>20</sub>H<sub>13</sub>F<sub>6</sub>N<sub>3</sub>O<sub>2</sub>S**nelivaptanum**


nelivaptan

(2*S*,4*R*)-1-[(3*R*)-5-chloro-1-[(2,4-dimethoxybenzene)sulfonyl]-3-(2-methoxyphenyl)-2-oxo-2,3-dihydro-1*H*-indol-3-yl]-4-hydroxy-*N,N*-dimethylpyrrolidine-2-carboxamide

né livaptan

(2*S*,4*R*)-1-[(3*R*)-5-cloro-1-[(2,4-diméthoxyphényl)sulfonyl]-3-(2-méthoxyphényl)-2-oxo-2,3-dihydro-1*H*-indol-3-yl]-4-hydroxy-*N,N*-diméthylpyrrolidine-2-carboxamide

nelivaptán

(2*S*,4*R*)-1-[(3*R*)-5-cloro-1-[(2,4-dimetoxibenceno)sulfoñil]-3-(2-metoxifenil)-2-oxo-2,3-dihidro-1*H*-indol-3-il]-4-hidroxi-*N,N*-dimetilpirrolidina-2-carboxamidaC<sub>30</sub>H<sub>32</sub>ClN<sub>3</sub>O<sub>8</sub>S**nesbuvirum**

nesbuvir


5-cyclopropyl-2-(4-fluorophenyl)-6-[*N*-(2-hydroxyethyl)metanesulfonamido]-*N*-methyl-1-benzofuran-3-carboxamide

nesbuvir

5-ciclopropil-2-(4-fluorofényl)-6-[(2-hidroxiétil)(méthylsulfonyl)amino]-*N*-méthyl-1-benzofurane-3-carboxamide

nesbuvir

5-ciclopropil-2-(4-fluorofenil)-6-[*N*-(2-hidroxietyl)metanosulfonamido]-*N*-metil-1-benzofuran-3-carboxamida

$C_{22}H_{23}FN_2O_5S$ **odanacatibum**


odanacatib

(2*S*)-*N*-(1-cyanocyclopropyl)-4-fluoro-4-méthyl-2-(((1*S*)-2,2,2-trifluoro-1-(4'-(méthanesulfonyl)-[1,1'-biphényl]-4-yl)éthyl)amino)pentanamide

odanacatib

(2*S*)-*N*-(1-cyanocyclopropyl)-4-fluoro-4-méthyl-2-(((1*S*)-2,2,2-trifluoro-1-[4'-(méthylsulfonyl)biphényl-4-yl]éthyl)amino)pentanamide

odanacatib

(2*S*)-*N*-(1-cianociclopropil)-4-fluoro-4-metil-2-(((1*S*)-2,2,2-trifluoro-1-[4'-(metanosulfonyl)-[1,1'-bifenil]-4-il]etil)amino)pentanamida $C_{25}H_{27}F_4N_3O_3S$ **omacetaxini mepesuccinas**

omacetaxine mepesuccinate


1-[(1*S*,3*aR*,14*bS*)-2-méthoxy-1,5,6,8,9,14*b*-hexahydro-4*H*-cyclopenta[*a*][1,3]dioxolo[4,5-*h*]pyrrolo[2,1-*b*][3]benzazépin-1-yl] 4-méthyl (2*R*)-2-hydroxy-2-(4-hydroxy-4-méthylpentyl)butanedioate

mépésuccinate d'omacétaxine

(2*R*)-2-hydroxy-2-(4-hydroxy-4-méthylpentyl)butanedioate de 1-[(1*S*,3*aR*,14*bS*)-2-méthoxy-1,5,6,8,9,14*b*-hexahydro-4*H*-cyclopenta[*a*][1,3]dioxolo[4,5-*h*]pyrrolo[2,1-*b*][3]benzazépin-1-yle] et de 4-méthyle

mepesuccinato de omacetaxina

(2*R*)-2-hidroxi-2-(4-hidroxi-4-metilpentil)butanodioato de 1-[(1*S*,3*aR*,14*bS*)-2-metoxi-1,5,6,8,9,14*b*-hexahidro-4*H*-ciclopenta[*a*][1,3]dioxolo[4,5-*h*]pirrolo[2,1-*b*][3]benzazépin-1-ilo] y de 4-metilo

C<sub>29</sub>H<sub>39</sub>NO<sub>9</sub>

**otelixizumabum\***  
otelixizumab

immunoglobulin G1, anti-(human CD3E) humanized/chimeric monoclonal TRX4 (ChAglyCD3); humanized gamma1 heavy chain 299N>A [humanized VH (*Homo sapiens* FR/*Rattus sp.* CDR) (119 residues [8.8.12])- *Homo sapiens* IGHG1\*01, 180N>A (CH2 84.4)] (222-216')-disulfide with chimeric lambda light chain 111G>R [*Rattus sp.* V-LAMBDA (110 residues [8.3.9])-*Homo sapiens* IGLC2\*01, 1G>R (1.5)] ; (228-228": 231-231")-bisdisulfide dimer

otélixizumab

immunoglobuline G1, anti-(CD3E humain) anticorps monoclonal humanisé/chimérique TRX4 (ChAglyCD3); chaîne lourde gamma1 humanisée 299N>A [VH humanisé (*Homo sapiens* FR/*Rattus sp.* CDR) (119 résidus [8.8.12])- *Homo sapiens* IGHG1\*01, 180N>A (CH2 84.4) (222-216')-disulfure avec la chaîne lambda chimérique 111G>R [*Rattus sp.* V-LAMBDA (110 résidus [8.3.9])-*Homo sapiens* IGLC2\*01, 1G>R (1.5)] ; dimère (228-228": 231-231")-bisdisulfure

otelixizumab

inmunoglobulina G1, anti-(CD3E humano) anticuerpo monoclonal humanizado/quimérico TRX4 (ChAglyCD3); cadena pesada gamma1 humanizada 299N>A [VH humanizada (*Homo sapiens* FR/*Rattus sp.* CDR) (119 residuos [8.8.12])- *Homo sapiens* IGHG1\*01, 180N>A (CH2 84.4) (222-216')-disulfuro con la cadena lambda quimérica 111G>R [*Rattus sp.* V-LAMBDA (110 residuos [8.3.9])-*Homo sapiens* IGLC2\*01, 1G>R (1.5)] ; dimero (228-228": 231-231")-bisdisulfuro

C<sub>6448</sub>H<sub>9954</sub>N<sub>1718</sub>O<sub>2016</sub>S<sub>42</sub>

Heavy chain / Chaîne lourde / Cadena pesada

EVQLLESGGG	LVQPGGSLRL	SCAASGFTFS	SFPMAWVRQA	PGKGLEWVST	50
ISTSGGRYY	RDSVKGRTI	SRDNSKNTLY	LQMNSLRAED	TAVYYCAKFR	100
QYSGGFDYWG	QGLTVTVSSA	STKGPSVFPL	APSSKSTSGG	TAALGCLVKD	150
YFPEPFTVSW	NSGALTSVGH	TFPAVLQSSG	LYSLSSVVTV	PSSSLGTQTY	200
ICNVNHRKPSN	TKVDKKEVEPK	SCDKTHTCPP	CPAPELLGGP	SVFLFPPKPK	250
DTLMIKSRPE	VTCVVDVSH	EDPEVKFNWY	VDGVEVHNAK	TKPREEQYAS	300
TYRVSVLTIV	LHQDWLNGKE	YKCKVSNKAL	PAPIEKTISK	AKGQPREPQV	350
YTLPPSRDEL	TKNQVSLTCL	VKGFYPSDIA	VEWESNGQPE	NNYKTTTPVL	400
DSDGSEFPLYS	KLTVDKSRWQ	QGNVPSCSVM	HEALHNHYTQ	KSLSLSPGK	449

Light chain / Chaîne légère / Cadena ligera

DIQLTQPNV	STSLGSTVKL	SCTLSSGNI	NNYVHWYQLY	EGRSPTTMIY	50'
DDDKRPDGP	DRFSGSIDRS	SNSAFLTIHN	VAIEDEAIYF	CHSYVSSFNV	100'
FGGGTKLTVL	RQPKAAPSVT	LFPPSSEELQ	ANKATLVCLI	SDFYPGAVTV	150'
AWKADSSPVK	AGVETTTPSK	QSNKYAASS	YLSLTPEQWK	SHRSYSCQVT	200'
HEGSTVEKTV	APTECS				216'

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

22-96 22"-96" 22'-91' 22"-91" 138'-197" 138"-197" 146-202 146"-202"  
215'-222 215"-222" 228-228" 231-231" 263-323 263"-323" 369-427 369"-427"

**pegloticasum\***

pegloticase


tetramer  $\alpha_4$  of des-(1-5)-[6-threonine,45-threonine,290-lysine,300-serine]uricase (EC 1.7.3.3, urate oxidase) from *Sus scrofa* (porcine), non acetylated, of which some of the lysine 6-amine residues are engaged in a carbamate linkage with a monomethyl ether of polyoxyethylene (macrogol)

pégloticase

tétramère  $\alpha_4$  du des-(1-5)-[6-thréonine,45-thréonine,290-lysine,300-sérine]uricase (EC 1.7.3.3, urate oxydase) de *Sus scrofa* (porc) non acétylé dont certaines fonctions 6-amine de lysines sont engagées dans une liaison carbamate avec un éther monométhyle de polyoxyéthylène (macrogol)

pegloticasa

tetrámero  $\alpha_4$  de la des-(1-5)-[6-treonina,45-treonina,290-lisina,300-serina]uricasa (EC 1.7.3.3, urato oxidasa) de *Sus scrofa* (porc) no acetilada algunas de cuyas funciones 6-amino de las lisinas forman uniones carbamato con un éter monometílico de polioxietileno (macrogol)

C<sub>6196</sub>H<sub>9720</sub>N<sub>1632</sub>O<sub>1792</sub>S<sub>32</sub>

H2N-R: Peptide monomer / Peptide monomère / Peptido monómero

TYKKN	DEVEFVRTGY	GKDMIKVLHI	QRDGKYHSIK	EVATTVQLTL	50
SSKKDYLHGD	NSDVIPTDTI	KNTVNVLAKF	KGIKSIETFA	VTICEHFLSS	100
FKHVIRAQVY	VEEVPWKRFE	KNGVKHVHAF	IYTPTGTHFC	EVEQIRNGPP	150
VIHSGIKDLK	VLKTTQSGFE	GFIKDQPTTL	PEVKDRCFAT	QVYCKWRYHQ	200
GRDVFEEATW	DTVRSIVLQK	FAGPYDKGEY	SPSVQKTLYD	IQVLTGLGQVP	250
EIEDMEISLP	NIHYLNIDMS	KMGLINKEEV	LLPLDNFYGK	ITGTVKRKLK	300
SRL					303

**preladenantum**

preladenant


2-(furan-2-yl)-7-(2-{4-[4-(2-methoxyethoxy)phenyl]piperazin-1-yl}ethyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine

préladénant

2-(furan-2-yl)-7-(2-{4-[4-(2-méthoxyéthoxy)phényl]pipérazin-1-yl}éthyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine

preladenant

2-(furan-2-il)-7-(2-{4-[4-(2-metoxietoxi)fenil]piperazin-1-il}etil)-7H-pirazolo[4,3-e][1,2,4]triazolo[1,5-c]pirimidin-5-amina

C<sub>25</sub>H<sub>29</sub>N<sub>9</sub>O<sub>3</sub>

**radiprodilum**


radiprodil

2-{4-[(4-fluorophenyl)methyl]piperidin-1-yl}-2-oxo-*N*-(2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)acetamide

radiprodil

2-{4-[(4-fluorophényl)méthyl]pipéridin-1-yl}-2-oxo-*N*-(2-oxo-2,3-dihydrobenzoxazol-6-yl)acétamide

radiprodil

2-{4-[(4-fluorofenil)metil]piperidin-1-il}-2-oxo-*N*-(2-oxo-2,3-dihidro-1,3-benzoxazol-6-il)acetamidaC<sub>21</sub>H<sub>20</sub>FN<sub>3</sub>O<sub>4</sub>**remogliflozini etabonas**


remogliflozin etabonate

5-methyl-1-(propan-2-yl)-4-({4-[(propan-2-yl)oxy]phenyl}methyl)-1*H*-pyrazol-3-yl 6-*O*-(ethoxycarbonyl)-β-*D*-glucopyranoside

étabonate de rémogliflozine

6-*O*-(éthoxycarbonyl)-β-*D*-glucopyranoside de 5-méthyl-4-[[4-(1-méthyléthoxy)phényl]méthyl]-1-(1-méthyléthyl)-1*H*-pyrazol-3-yle

etabonato de remogliflozina

6-*O*-(etoxicarbonil)-β-*D*-glucopiranosido de 5-metil-1-(propan-2-il)-4-({4-[(propan-2-il)oxi]fenil}metil)-1*H*-pirazol-3-iloC<sub>26</sub>H<sub>38</sub>N<sub>2</sub>O<sub>9</sub>**retosibanum**

retosiban

(3*R*,6*R*)-6-[(2*S*)-butan-2-yl]-3-(2,3-dihydro-1*H*-inden-2-yl)-1-[(1*R*)-1-(2-methyl-1,3-oxazol-4-yl)-2-(morpholin-4-yl)-2-oxoethyl]piperazine-2,5-dione


rétosiban

(3*R*,6*R*)-3-(2,3-dihydro-1*H*-indén-2-yl)-1-[(1*R*)-1-(2-méthyloxazol-4-yl)-2-(morpholin-4-yl)-2-oxoéthyl]-6-[(1*S*)-1-méthylpropyl]=pipérazine-2,5-dione

retosibán

(3*R*,6*R*)-6-[(2*S*)-butan-2-il]-3-(2,3-dihidro-1*H*-inden-2-il)-1-[(1*R*)-1-(2-metil-1,3-oxazol-4-il)-2-(morfolin-4-il)-2-oxoetil]piperazina-2,5-diona



$C_{27}H_{34}N_4O_5$ **riociguatum**


riociguat

methyl *N*-(4,6-diamino-2-{1-[(2-fluorophenyl)methyl]-1*H*-pyrazolo[3,4-*b*]pyridin-3-yl}pyrimidin-5-yl)-*N*-methylcarbamate

riociguat

(4,6-diamino-2-{1-[(2-fluorophényl)méthyl]-1*H*-pyrazolo[3,4-*b*]pyridin-3-yl}pyrimidin-5-yl)méthylcarbamate de méthyle

riociguat

(4,6-diamino-2-{1-[(2-fluorofenil)metil]-1*H*-pirazolo[3,4-*b*]piridin-3-il}pirimidin-5-il)metilcarbamato de metilo $C_{20}H_{19}FN_8O_2$ **rolofyllinum**


rolofylline

1,3-dipropyl-8-(tricyclo[3.3.1.0<sup>3,7</sup>]nonan-3-yl)-3,7-dihydro-1*H*-purine-2,6-dione

rolofylline

1,3-dipropyl-8-(tricyclo[3.3.1.0<sup>3,7</sup>]non-3-yl)-3,7-dihydro-1*H*-purine-2,6-dione

rolofyllina

1,3-dipropil-8-(tricyclo[3.3.1.0<sup>3,7</sup>]nonan-3-il)-3,7-dihidro-1*H*-purina-2,6-diona $C_{20}H_{28}N_4O_2$ 

tenatumomabum* tenatumomab	immunoglobulin G2b, anti-[human tenascin C (TNC, hexabrachion, HBX) <i>Mus musculus</i> ] monoclonal antibody ST2146; gamma2b heavy chain ( <i>Mus musculus</i> VH [8.8.13]-IGHG2B*02 from clone ST2146) (135-219')-disulfide with kappa light chain ( <i>Mus musculus</i> V-KAPPA [11.3.9]-IGKC*01 from clone ST 2146); (229-229'':232-232'':235-235'':238-238'')-tetradisulfide dimer
ténatumomab	immunoglobuline G2b, anti-[tenascine C humaine (TNC, hexabrachion, HBX) <i>Mus musculus</i> ] anticorps monoclonal murin ST2146; chaîne lourde gamma2b ( <i>Mus musculus</i> VH [8.8.13]-IGHG2B*02 du clone ST2146) (135-219')-disulfure avec la chaîne légère kappa ( <i>Mus musculus</i> V-KAPPA [11.3.9]-IGKC*01 du clone ST 2146); dimère (229-229'':232-232'':235-235'':238-238'')-tétradisulfide
tenatumomab	inmunoglobulina G2b, anti-[tenascina C humana (TNC, hexabrachion, HBX) <i>Mus musculus</i> ] anticuerpo monoclonal murino ST2146; cadena pesada gamma2b ( <i>Mus musculus</i> VH [8.8.13]-IGHG2B*02 del clon ST2146) (135-219')-disulfuro con la cadena ligera kappa ( <i>Mus musculus</i> V-KAPPA [11.3.9]-IGKC*01 del clon ST 2146); dímero (229-229'':232-232'':235-235'':238-238'')-tetradisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

EIQ	LQ	QSGPE	LVKPGASVKV	SCKASGYAFT	SYNMYWVKQS	HGKSLEWIGY	50	
IDPY	NGVTSY	NQKFKGKATL	TVDKSSSTAY	MHLNSLTSED	SAVYYCARGG		100	
GSIYY	AMDYW	GQGTSTVTVSS	AKTTPPSVYP	LAPGCGDITG	SSVTLGCLVK		150	
GYFP	ESVTVT	WNSGSLSSSV	HTFPALLQSG	LYTMS <sup>S</sup> SVTV	PSSTWPSQTV		200	
TC	SV	AHPASS	TTVDKKLEPS	GPISTINPCP	PCKECHKCPA	PNLEGGPSVF	250	
IF	FP	NIKDV	L	MISLTPKVT	VVVDVSEDDP	DVQISWFWNN	VEVHTAQQT	300
HRE	DY	NSTIR	VVSTLPIQH	DWMSGKEFKC	KVNNKDLSP	IERTISKIKG		350
LVR	AP	QVYIL	PPPAEQLSRK	DVSLTCLVVG	FNPGDISVEW	TSNGHTEENY		400
KDT	AP	VLDSD	GSYFIYSKLN	MKTSKWEKTD	SFSCNVRHEG	LKNYYLKKTI		450
SR	SP	PK					456	

Light chain / Chaîne légère / Cadena ligera

DIV	MTQAAPS	VPVTPGESVS	ISCRSSKSL	HSNGNTYLYW	FLQRPQGSPQ		50
LLI	YRMSNLA	SGVPDRFSGS	GSGTAFTLRI	SRVEAEDVGV	YYCMQHLEYP		100
LTF	GAGTKLE	LKRDAAPT	V	SIFPPSSSEQL	TSGGASVVF	LNNFYPKDIN	150
VK	WKIDGSR	QNGVLNSWTD	QDSKDSTYSM	SSTLTTLTKDE	YERHNSYTCE		200
ATH	KTSTSPI	VKSFNRNE	C				219

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro  
Bold and underlined **Cysteins** are those involved in disulphide bridges.

tertomotidum tertomotide	human telomerase reverse transcriptase (EC 2.7.7.49)-(611-626)-peptide (telomerase catalytic subunit fragment)
tertomotide	téломérase transcriptase réverse humaine (EC 2.7.7.49)-(611-626)-peptide (fragment de la sous-unité catalytique de la télomérase)
tertomotida	transcriptasa inversa humana telomerasa (EC 2.7.7.49)-(611-626)-péptido (fragmento de la subunidad catalítica de la telomerasa)

C<sub>85</sub>H<sub>146</sub>N<sub>26</sub>O<sub>21</sub>

H—Glu—Ala—Arg—Pro—Ala—Leu—Leu—Thr—Ser—

Arg—Leu—Arg—Phe—Ile—Pro—Lys—OH

10

16

<b>tigatuzumabum*</b> tigatuzumab	immunoglobulin G1, anti-[ <i>Homo sapiens</i> TNFRSF10B (tumor necrosis factor receptor superfamily member 10b, DR5, TRAIL-R2, CD262)] humanized monoclonal TRA-8 (or CS-1008); gamma1 heavy chain [humanized VH ( <i>Homo sapiens</i> FR/ <i>Mus musculus</i> CDR) [8.8.12] - <i>Homo sapiens</i> IGHG1*03] (222-213')-disulfide with kappa light chain [humanized V-KAPPA ( <i>Homo sapiens</i> FR/ <i>Mus musculus</i> CDR) [6.3.8] - <i>Homo sapiens</i> IGKC*01]; (228-228":231-231")-bisdisulfide dimer
tigatuzumab	immunoglobuline G1, anti-[ <i>Homo sapiens</i> TNFRSF10B (membre 10b de la superfamille des récepteurs du facteur de nécrose tumorale, DR5, TRAIL-R2, CD262)] anticorps monoclonal humanisé TRA-8 (ou CS-1008); chaîne lourde gamma1 [VH humanisé ( <i>Homo sapiens</i> FR/ <i>Mus musculus</i> CDR) [8.8.12] - <i>Homo sapiens</i> IGHG1*03] (222-213')-disulfure avec la chaîne légère kappa [V-KAPPA humanisé ( <i>Homo sapiens</i> FR/ <i>Mus musculus</i> CDR) [6.3.8] - <i>Homo sapiens</i> IGKC*01]; dimère (228-228":231-231")-bisdisulfure
tigatuzumab	inmunoglobulina G1, anti-[ <i>Homo sapiens</i> TNFRSF10B (miembro 10b de la superfamilia de receptores del factor de necrosis tumoral, DR5, TRAIL-R2, CD262)] anticuerpo monoclonal humanizado TRA-8 (o CS-1008); cadena pesada gamma1 [VH humanizada ( <i>Homo sapiens</i> FR/ <i>Mus musculus</i> CDR) [8.8.12] - <i>Homo sapiens</i> IGHG1*03] (222-213')-disulfuro con la cadena ligera kappa [V-KAPPA humanizada ( <i>Homo sapiens</i> FR/ <i>Mus musculus</i> CDR) [6.3.8] - <i>Homo sapiens</i> IGKC*01]; dímero (228-228":231-231")-bisdisulfuro
	C <sub>6406</sub> H <sub>9924</sub> N <sub>1716</sub> O <sub>2012</sub> S <sub>46</sub>
	Heavy chain / Chaîne lourde / Cadena pesada
	EVQLVESGGG LVQPGGSLRL SCAASGFTFS SYVMSWVRQA PGKGLEWVAT 50
	ISSGGSYTY Y PDSVKGRFTI SRDRAKNTLY LQMNSLRAED TAVYVCARRG 100
	DSMITTDYWG QGTLVTVSSA STKGPSVFPFL APSSKSTSGG TAAALGCLVKD 150
	YFPEPVTVSW NSGALTSGVH TFPAVLQSSG LYSLSSTVTV PSSLGTQTY 200
	ICNVNHPKSN TKVDKRVPEK SCDKTHTCPP CPAPELLGGP SVFLFPFKPK 250
	DTLMLSRPTE VTCVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS 300
	TYRVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV 350
	YTLPPSREEM TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTPPVVL 400
	DSDGSFFLYS KLTVDKSRWQ QGNVVFSCSVM HEALHNHYTQ KSLSLSPGK 449
	Light chain / Chaîne légère / Cadena ligera
	DIQMTQSPSS LSASVGRVIT ITCKASQDVG TAVAWYQQKP GKAPKLLIYW 50'
	ASTRHTGVPF RFGSGSGTD FTLTISSLQP EDFATYYCQQ YSSYRTFGQG 100'
	TKVEIKRTVA APSVFIFPPS DEQLKSGTAS VVCLLNFPY REAKVQWKVD 150'
	NALQSGNSQE SVTEQDSKDS TYSLSTLTL SKADYEKHKV YACEVTHQGL 200'
	SSPVTKSNR GEC 213'
	Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
	22-96 22"-96" 23'-88" 23"-88" 133'-193" 133"-193" 146-202 146"-202"
	213'-222 213"-222" 228-228" 231-231" 263-323 263"-323" 369-427 369"-427"
<b>velaglycerasum alfa*</b> velaglycerase alfa	human glucosylceramidase (EC 3.2.1.45 or beta-glucocerebrosidase), glycoform $\alpha$
velaglycerase alfa	glucosylcéramidase humaine (EC 3.2.1.45 ou bêta-glucocérébrosidase), glycoform $\alpha$
velaglycerasa alfa	glucosilceramidasa humana (EC 3.2.1.45 o beta-glucocerebrosidasa), glicofoma $\alpha$

C<sub>2532</sub>H<sub>3850</sub>N<sub>672</sub>O<sub>711</sub>S<sub>16</sub>

ARPCIPKSFSG	YSSVVCVNA	TYCDSFDPPT	FPALGTFSTRY	ESTRSGRRME	50
LSMGPIQANH	TGTGLLLTLQ	PEQKFQKVKG	FGGAMTDAAA	LNILALSPPA	100
QNLLKSYFS	EEGIGYNIIR	VPASCDFSI	RTYTYADTPD	DFQLHNFSLP	150
EEDTKLKIPL	IHRALQLAQR	PVSLLASPWT	SPTWLKTNGA	VNGKGSLLKGG	200
PGDIYHQTWA	RYFVKFLDAY	AEHKLQFWAV	TAENEPSAGL	LSGYPFQCLG	250
FTPEHQDFI	ARDLGPPTLAN	STHHNVRLIM	LDDQRLLLPH	WAKVVLTDP	300
AAKYVHGIAV	HWYLDLFLAPA	KATLGETHRL	FPNTMLFASE	ACVGSKWEQ	350
SVRLGSWDRG	MQYSHSLITN	LLYHVVGWTD	WNLALNPEGG	PNWVRNFVDS	400
PIIVDITKDT	FYKQPMFYHL	GHFSEFIPEG	SQRVGLVASQ	KNDLDAVALM	450
HPDGSVAVVV	LNRSSKDVPL	TIKPPAVGFL	ETISPGYSIH	TYLWRRQ	497

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro  
4-16 18-23

Glycosylation sites / Sites de glycosylation / Posiciones de glicosilación  
Asn-19 Asn-59 Asn-146 Asn-270 Asn-462

**veltuzumabum\***

veltuzumab

immunoglobulin G1, anti-*[Homo sapiens* CD20 (MS4A1, membrane-spanning 4-domains subfamily A member 1, B lymphocyte surface antigen B1, Leu-16, Bp35)] humanized monoclonal IMMU-106 (or hA20); gamma1 heavy chain [humanized VH (*Homo sapiens* FR/*Mus musculus* CDR) [8.8.14] -*Homo sapiens*IGHG1\*03] (224-213')-disulfide with kappa light chain [humanized V-KAPPA (*Homo sapiens* FR/*Mus musculus* CDR) [5.3.9] -*Homo sapiens* IGKC\*01]; (230-230":233-233")-bisdisulfide dimer

veltuzumab

immunoglobuline G1, anti-*[Homo sapiens* CD20 (MS4A1, membre 1 de la sous-famille A à 4 domaines transmembranaires, antigène de surface B1 des lymphocytes B, Leu-16, Bp35)] anticorps monoclonal humanisé IMMU-106 (ou hA20); chaîne lourde gamma1 [VH humanisé (*Homo sapiens* FR/*Mus musculus* CDR) [8.8.14] - *Homo sapiens*IGHG1\*03] (224-213')-disulfure avec la chaîne légère kappa [V-KAPPA humanisé (*Homo sapiens* FR/*Mus musculus* CDR) [5.3.9] -*Homo sapiens* IGKC\*01]; dimère (230-230":233-233")-bisdisulfure

veltuzumab

inmunoglobulina G1, anti-*[Homo sapiens* CD20 (MS4A1, miembro 1 de la subfamilia A con 4 dominios transmembranarios, antígeno de superficie B1 de los linfocitos B, Leu-16, Bp35)] anticuerpo monoclonal humanizado IMMU-106 (ou hA20); cadena pesada gamma1 [VH humanizado (*Homo sapiens* FR/*Mus musculus* CDR) [8.8.14] - *Homo sapiens*IGHG1\*03] (224-213')-disulfuro con la cadena ligera kappa [V-KAPPA humanizado (*Homo sapiens* FR/*Mus musculus* CDR) [5.3.9] -*Homo sapiens* IGKC\*01]; dímero (230-230":233-233")-bisdisulfuro

C<sub>6458</sub>H<sub>9918</sub>N<sub>1706</sub>O<sub>2026</sub>S<sub>46</sub>

Heavy chain / Chaîne lourde / Cadena pesada					
QVQLQQSGAE	VKKPGSSVKV	SCKASGYTFT	SYNMHWVKA	PGQGLEWIGA	50
IYFGMGTDSY	NQKFKGKATL	TADESTNTAY	MELSSLRSED	TAFYYCARST	100
YYGGDWYFDV	WQGTTVTVS	SASTKGPSVF	PLAPSSKSTS	GGTAALGCLV	150
KDYFPEPVTV	SWNSGALTS	VHTFPAVLQS	SGLYSLSSVV	TPSSSLGTQ	200
TYICNVNHKP	SNTKVDKRV	PKSCDKHTC	PPCPAPELLG	GPSVPLFPPK	250
PKDITLMSRT	PEVTCVVVDV	SHEDPEVKFN	WYVDGVEVHN	AKTKPREEQY	300
NSTYRVVSVL	TVLHQDWLNG	KEYKCKVSNK	ALPAPIEKTI	SKAKGQPREP	350
QVYTLPPSRE	EMTKNQVSLT	CLVKGFYPSD	IAVEWESNGQ	PENNYKTTTP	400
VLDSDGSFPL	YSKLTVDKSR	WQQGNVFS	VMHEALHNYH	TQKSLSLSPG	450
K					451

Light chain / Chaîne légère / Cadena ligera					
DIQLTQSPSS	LSASVGDRVT	MTCRASSVVS	YIHWFQQKPG	KAPKPIYAT	50'
SNLASGVFVR	FSGSGGTIDY	TFTISLQPE	DIATYICQQW	TSNPTTFGGG	100'
TKLEIKRTVA	APSVFIFPPS	DEQLKSGTAS	VVCLLNNFYF	REAKQVQKVD	150'
NALQSGNSQE	SVTEQDSKDS	TYSLSTLTL	SKADYEKHKV	YACEVTHQGL	200'
SSPVTKSFNR	GEC				213'

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro  
22-96 22"-96" 23-87" 23"-87" 133-193" 133"-193" 148-204 148"-204"  
213'-224 213"-224" 230-230" 233-233" 265-325 265"-325" 371-429 371"-429"

**viqidacinum**

viqidacin


(3*R*,4*R*)-4-[(3*S*)-3-[3-fluoro-6-methoxyquinolin-4-yl]-3-hydroxypropyl]-1-[2-[(thiophen-2-yl)sulfanyl]ethyl]piperidine-3-carboxylic acid

viqidacine

acide (3*R*,4*R*)-4-[(3*S*)-3-(3-fluoro-6-méthoxyquinoléin-4-yl)-3-hydroxypropyl]-1-[2-(thiophén-2-ylsulfanyl)éthyl]pipéridine-3-carboxylique

viqidacina

ácido (3*R*,4*R*)-4-[(3*S*)-3-[3-fluoro-6-metoxiquinolin-4-il]-3-hidroxiopropil]-1-[2-[(tiofen-2-il)sulfanil]etil]piperidina-3-carboxílico

 $C_{25}H_{29}FN_2O_4S_2$ 

---

**AMENDMENTS TO PREVIOUS LISTS  
MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES  
MODIFICACIONES A LAS LISTAS ANTERIORES**

**Recommended International Nonproprietary Names (Rec. INN): List 59**  
**Dénominations communes internationales recommandées (DCI Rec.): Liste 59**  
**Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 59**  
*(WHO Drug Information, Vol. 22, No. 1, 2008)*

p. 43	<i>suprimáse</i> albinterferón alfa2b	<i>insertése</i> albinterferón alfa-2b
p. 48	<i>supprimer</i> céftaroline fosamil	<i>insérer</i> ceftaroline fosamil

- \* Electronic structure available on Mednet: <http://mednet.who.int/>
- \* Structure électronique disponible sur Mednet: <http://mednet.who.int/>
- \* Estructura electrónica disponible en Mednet: <http://mednet.who.int/>

**Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales**

The text of the *Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances* and *General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical Substances* will be reproduced in proposed INN lists only.

Les textes de la *Procédure à suivre en vue du choix de dénominations communes internationales recommandées pour les substances pharmaceutiques* et des *Directives générales pour la formation de dénominations communes internationales applicables aux substances pharmaceutiques* seront publiés seulement dans les listes des DCI proposées.

El texto de los *Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sustancias farmacéuticas* y de los *Principios generales de orientación para formar denominaciones comunes internacionales para sustancias farmacéuticas* aparece solamente en las listas de DCI propuestas.